Search and analyze individual stocks with comprehensive metrics

Auro Laboratories Limited

AUROLABPharmaceuticals

Fundamental Score

...

Auro Laboratories Limited Share Price & Market Analysis

Current Market Price (CMP)
251.70
No change data available
Market Cap
156.37 (Cr)
Industry
Pharmaceuticals

Profitability Metrics

Return on Equity

N/A

Return on Capital Employed

N/A

Operating Profit Margin (5Y)

N/A
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

71.08x

Market Capitalization

156.37 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

100.00%
Excellent

YoY Quarterly Sales Growth

185.16%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

1.01x
Average

Interest Coverage

2.74x

Free Cash Flow (5Y)

N/A

Ownership Structure

Good

Promoter Holding

52.18%
Poor

FII Holding

0.00%
Poor

DII Holding

0.01%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
52.18%
Promoter Holding
156.37 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of AUROLAB across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Robust Profit Growth (100.00%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (185.16%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Balanced Promoter Holding (52.18%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

7 factors identified

Premium Valuation Risk (P/E: 71.08x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

Elevated Debt Levels (D/E: 1.01)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.

Limited Institutional Interest (FII+DII: 0.01%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Auro Laboratories Limited

About AUROLAB

Company Details

Symbol:AUROLAB
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Market Information

Market Cap:156.37 (Cr)
P/E Ratio:71.08
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.00%

AUROLAB Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)N/A%
Return on Capital EmployedN/A%
Operating Profit Margin (5Y)N/A%
Debt to Equity Ratio1.01
Interest Coverage Ratio2.74

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth100.00%
YoY Quarterly Sales Growth185.16%

Frequently Asked Questions

What is the current price of AUROLAB?

AUROLAB is currently trading at ₹251.70 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of AUROLAB shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of AUROLAB and what does it mean?

AUROLAB has a P/E ratio of 71.08x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹71 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.

How is AUROLAB performing according to Bull Run's analysis?

AUROLAB has a Bull Run fundamental score of 24.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: N/A%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does AUROLAB belong to?

AUROLAB operates in the Pharmaceuticals industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Auro Laboratories Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for AUROLAB?

AUROLAB has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Auro Laboratories Limited generates profits from shareholders' equity. An ROE of N/A% means the company generates ₹N/A profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is AUROLAB's debt-to-equity ratio and what does it indicate?

AUROLAB has a debt-to-equity ratio of 1.01, which indicates high leverage that increases financial risk. This means the company has ₹101 of debt for every ₹100 of equity. Higher leverage can amplify returns during good times but increases bankruptcy risk during downturns.

What is AUROLAB's dividend yield and is it a good dividend stock?

AUROLAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has AUROLAB grown over the past 5 years?

AUROLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in AUROLAB and why does it matter?

Promoters hold 52.18% of AUROLAB shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does AUROLAB compare with its industry peers?

AUROLAB trades at P/E 71.08x vs industry average 31.77x, with ROE of N/A% and ROCE of N/A%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether AUROLAB is outperforming its competitive set in profitability, growth, and valuation metrics.

What is AUROLAB's market capitalization and what category does it fall into?

AUROLAB has a market capitalization of ₹156 crores, making it a Mid-cap stock. Mid-cap stocks balance growth potential with moderate risk. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for AUROLAB?

Key ratios for AUROLAB: ROE N/A% (Needs improvement), ROCE N/A%, P/E 71.08x, Debt-to-Equity 1.01, Interest Coverage 2.74x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is AUROLAB stock and what is its beta?

AUROLAB has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for AUROLAB?

AUROLAB has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹251.70, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in AUROLAB?

Key risks for AUROLAB include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 1.01), and operational challenges. The stock has a Fundamental Score of 24.5/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is AUROLAB's operating profit margin and how has it trended?

AUROLAB has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.

How is AUROLAB's quarterly performance in terms of sales and profit growth?

AUROLAB's recent quarterly performance shows YoY Sales Growth of 185.16% and YoY Profit Growth of 100.00%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in AUROLAB?

AUROLAB has FII holding of 0.00% and DII holding of 0.01%, totaling 0.01% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.